Literature DB >> 9212316

Conservative management of osteomyelitis in the feet of diabetic patients.

P Venkatesan1, S Lawn, R M Macfarlane, E M Fletcher, R G Finch, W J Jeffcoate.   

Abstract

Experience of conservative management of osteomyelitis in a specialized, multidisciplinary, diabetic foot clinic was reviewed. The records of all patients attending the clinic over a 10-year period were examined retrospectively, and 22 patients with overt osteomyelitis were identified. Median age was 66 (31-87) years. In 12 cases the bone infection was a complication of a pre-existing ulcer; the most prevalent organism cultured from swabs was Staphylococcus aureus. The main site of infection was the first toe. The total duration of antibiotic treatment was 12 weeks (median, range 5-72), and clindamycin was the most commonly used oral agent. Four patients did not respond to initial conservative therapy and proceeded to amputation, while 1 patient responded clinically but had a recurrence of osteomyelitis at the same site 6 years later. In the remaining 17 patients resolution of osteomyelitis was achieved with conservative management over a median period of follow-up of 27 (range 5-73) months. The success of conservative therapy with prolonged courses of oral antibiotics challenges conventional advice that excision of infected bone is essential in the management of osteomyelitis affecting the foot in diabetes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9212316     DOI: 10.1002/(SICI)1096-9136(199706)14:6<487::AID-DIA373>3.0.CO;2-Q

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  16 in total

1.  Ceftobiprole: First reported experience in osteomyelitis.

Authors:  A Macdonald; G Dow
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

2.  Chronic osteomyelitis.

Authors:  Ilker Uçkay; Kheeldass Jugun; Axel Gamulin; Joe Wagener; Pierre Hoffmeyer; Daniel Lew
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

3.  Diabetic foot ulcers: practical treatment recommendations.

Authors:  Michael Edmonds
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Optimal treatment of infected diabetic foot ulcers.

Authors:  Edward B Jude; Philip F Unsworth
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

5.  Osteomyelitis of the foot and toe in adults is a surgical disease: conservative management worsens lower extremity salvage.

Authors:  Peter K Henke; Susan A Blackburn; Reid W Wainess; John Cowan; Alicia Terando; Mary Proctor; Thomas W Wakefield; Gilbert R Upchurch; James C Stanley; Lazar J Greenfield
Journal:  Ann Surg       Date:  2005-06       Impact factor: 12.969

6.  Are We Misdiagnosing Diabetic Foot Osteomyelitis? Is the Gold Standard Gold?

Authors:  Lawrence A Lavery; P Andrew Crisologo; Javier La Fontaine; Kavitha Bhavan; Orhan K Oz; Kathryn E Davis
Journal:  J Foot Ankle Surg       Date:  2019-07       Impact factor: 1.286

7.  Application of white blood cell SPECT/CT to predict remission after a 6 or 12 week course of antibiotic treatment for diabetic foot osteomyelitis.

Authors:  Julien Vouillarmet; Myriam Moret; Isabelle Morelec; Paul Michon; Julien Dubreuil
Journal:  Diabetologia       Date:  2017-09-02       Impact factor: 10.122

8.  Primarily non-surgical management of osteomyelitis of the foot in diabetes.

Authors:  F L Game; W J Jeffcoate
Journal:  Diabetologia       Date:  2008-04-03       Impact factor: 10.122

Review 9.  The treatment of diabetic foot infections: focus on ertapenem.

Authors:  Michael Edmonds
Journal:  Vasc Health Risk Manag       Date:  2009-11-16

10.  Outcomes of surgical treatment of diabetic foot osteomyelitis: a series of 185 patients with histopathological confirmation of bone involvement.

Authors:  F J Aragón-Sánchez; J J Cabrera-Galván; Y Quintana-Marrero; M J Hernández-Herrero; J L Lázaro-Martínez; E García-Morales; J V Beneit-Montesinos; D G Armstrong
Journal:  Diabetologia       Date:  2008-08-22       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.